Pathalys Pharma
PrivateLast Round
Series B
Aug 20, 2024
Est. Valuation
$295M
Total Funding Raised
$255M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pathalys Pharma is a biopharmaceutical company that develops advanced therapeutics to address unmet needs in the management of end-stage kidney disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathalys Pharma Comparables
Compare Pathalys Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kissei Pharmaceutical | 79% | |
| Amgen | 77% | |
| Eisai | 76% |
Pathalys Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 20, 2024 | ||||
| Early Funding | Jan 18, 2023 | ||||
| Seed | Mar 1, 2022 |
Pathalys Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Post Investment Corporation | Series B |
| TCG Crossover | Series B |
| KB Investment | Series B |
| KB Investment | Series B |
| OrbiMed | Early Funding |
| Japan Post Bank Asset Management Co., Ltd. | Series B |
| The Carlyle Group | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 66% MoM.
- Jul 27, 2026
Monthly visitors grew 424% MoM, from 283 to 1.5K.
Pathalys Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Pathalys Pharma's valuation, stock price, and market status.
Is Pathalys a public or private company?
Pathalys is a private company.
What is the current stock price of Pathalys?
Pathalys is a private company with no public stock price. No recent secondary market data is available.
How much is Pathalys worth (valuation)?
Valuation information for Pathalys is not publicly available.
Can I buy Pathalys stock?
Pathalys shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Pathalys's last funding round?
Pathalys's most recent funding round was Series B on August 20, 2024.
Who are the main investors in Pathalys?
Key investors in Pathalys include TCG Crossover, Abingworth.
Will Pathalys IPO soon?
No public IPO plans have been announced for Pathalys.
How can I track Pathalys secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pathalys's secondary market activity and sign up for updates.